High-Sensitivity Cardiac Troponin T Assessment to Improve Cardiovascular Risk Prognostication in Patients with Chronic Kidney Disease: Ready for Prime Time?
Restricted accessEditorialFirst published online April, 2022
High-Sensitivity Cardiac Troponin T Assessment to Improve Cardiovascular Risk Prognostication in Patients with Chronic Kidney Disease: Ready for Prime Time?
KozinskiMKrintusMKubicaJSypniewskaG. High-sensitivity cardiac troponin assays: from improved analytical performance to enhanced risk stratification. Crit Rev Clin Lab Sci. 2017;54:143-172.
2.
CollinsonP. High sensitivity troponin, analytical advantages, clinical benefits and clinical challenges - An update. Clin Biochem. 2021;91:1-8.
3.
BallewSHMatsushitaK. Cardiovascular Risk Prediction in CKD. Semin Nephrol. 2018;38:208-216.
4.
KulaAJKatzRZelnickLR, et al.Association of circulating cardiac biomarkers with electrocardiographic abnormalities in chronic kidney disease. Nephrol Dial Transplant. 2020. doi:10.1093/ndt/gfaa296. Online ahead of print.
5.
SteinNRZelnickLRAndersonAH, et al.Associations between cardiac biomarkers and cardiac structure and function in CKD. Kidney Int Rep. 2020;5:1052-1060.
6.
BansalNHyre AndersonAYangW, et al.High-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and risk of incident heart failure in patients with CKD: the chronic renal insufficiency cohort (CRIC) study. J Am Soc Nephrol. 2015;26:946-956.
7.
BansalNZelnickLGoA, et al.Cardiac biomarkers and risk of incident heart failure in chronic kidney disease: the CRIC (chronic renal insufficiency cohort) study. J Am Heart Assoc. 2019;8:e012336.
8.
BansalNZelnickLShlipakMG, et al.Cardiac and stress biomarkers and chronic kidney disease progression: the CRIC study. Clin Chem. 2019;65:1448–1457.
9.
WangKZelnickLRAndersonA, et al.Cardiac biomarkers and risk of mortality in CKD (the CRIC study). Kidney Int Rep. 2020;5:2002-2012.
10.
GreggLPAdams-HuetBLiX, et al.Effect modification of chronic kidney disease on the association of circulating and imaging cardiac biomarkers with outcomes. J Am Heart Assoc. 2017;6:e005235.
11.
HajjariJJanusSEAlbarZAl-KindiSG. Myocardial injury and the risk of stroke in patients with chronic kidney disease (from the chronic renal insufficiency cohort study). Angiology. 2022;73:312–317.
12.
TripepiGPannierBD’ArrigoGMallamaciFZoccaliCLondonG. Reappraisal in two European cohorts of the prognostic power of left ventricular mass index in chronic kidney failure. Kidney Int. 2017;91:704-710.
13.
TripepiGAgharaziiMPannierB, et al.Pulse wave velocity and prognosis in end-stage kidney disease. Hypertension. 2018;71:1126-1132.
14.
GeorgianosPIVaiosVEleftheriadisTZebekakisPELiakopoulosV. Pulse wave velocity assessment for cardiovascular risk prognostication in ESKD: weighting recent evidence. Curr Vasc Pharmacol. 2021;19:4–11.
15.
BansalNZelnickLRSolimanEZ, et al.Change in cardiac biomarkers and risk of incident heart failure and atrial fibrillation in CKD: the chronic renal insufficiency cohort (CRIC) study. Am J Kidney Dis. 2021;77:907-919.
16.
PackerMAnkerSDButlerJ, et al.Cardiovascular and renal outcomes with empagliflozin in heart failure. New Engl J Med. 2020;383:1413-1424.
17.
PackerMJanuzziJLJr.FerreiraJP, et al.Concentration‐dependent clinical and prognostic importance of high‐sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR‐reduced trial[Online ahead of print]. Eur J Heart Fail2021. doi:10.1002/ejhf.2256.
